FRI0352 Treatment of refractory takayasu arteritis with tocilizumab: seven italian patients from a single referral center.

Background

Takayasu arteritis (TA) is an inflammatory large-vessel panarteritis resulting in vessel stenosis, occlusion or aneurysm formation¹. Medical therapy with steroids and immunosuppressive agents is the cornerstone of TA although a significant proportion of patients (pts) are refractory to these regimes¹. Observations on small groups of TA pts suggest the efficacy of tocilizumab (TCZ), a humanized anti-IL6...